Andrew Eichholz

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The linear effects of <i>α</i>‐thalassaemia, the <i>UGT1A1</i> and <i>HMOX1</i> polymorphisms on cholelithiasis in sickle cell disease

Nisha Vasavda, Stephan Menzel, Emma G. Maytham et al. · British Journal of Haematology · 2007 · 82 citations

Medicine, Genetics, Hematology +15

Dihydroquercetin as a means of antioxidative defence in rats with tetrachloromethane hepatitis

Yu. О. Teselkin, I. V. Babenkovа, V. K. Kolhir et al. · Phytotherapy Research · 2000 · 78 citations

Veterinary Medicine, Pharmacology, Toxicology +17

Anti-angiogenesis therapies: their potential in cancer management

Andrew Gaya, Andrew Eichholz, Merchant · OncoTargets and Therapy · 2010 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

Nalinie Joharatnam‐Hogan, Duaa Hatem, Fay Cafferty et al. · British Journal of Cancer · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17